HALO Halozyme Therapeutics, Inc.
HALO Halozyme Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $69.40 · VWAP $72.16 · +42.7% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
HALO Price Structure
Loading timeframes…
Peers
Every watchlist HALO belongs to, members best 30-day change first — HALO highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported EPS $2.28 versus analyst consensus of $1.82 (+25.5%).
full note →Against street estimates
How HALO's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about HALO from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 10 days ago · Aug 8
HALO research tape
10 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.